Publications by authors named "David Blakey"

Claim this Profile
P
PSMA-PET Detection of Unusual Metastases in Castrate-Sensitive Prostate Carcinoma.
Nathanial Harris, Mun Yee Tan, Michael Ng, David Blakey, Mario Guerrieri

Clin Nucl Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing SIRT1 Gene Expression Using Small Activating RNAs: A Novel Approach for Reversing Metabolic Syndrome.
Pinelopi Andrikakou, Vikash Reebye, Daniel Vasconcelos, Sorah Yoon, Jon Voutila, David Blakey

Nucleic Acid Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models.
Kai-Wen Huang, Choon Ping Tan, Vikash Reebye, Cheng Ean Chee, Dimitris Zacharoulis, David C Blakey

Int J Mol Sci· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial.
Debashis Sarker, Ruth Plummer, Tim Meyer, Mikael H Sodergren, Bristi Basu, David C Blakey

Clin Cancer Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.
Alexandre J Debacker, Jon Voutila, Matthew Catley, David Blakey, Nagy Habib

Mol Ther· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adoption of hypofractionated radiation therapy for early breast cancer in private practice: the GenesisCare experience 2014–2016.
Katherine Neville, Marcus Dreosti, David Blakey, Margaret Latham, Michael A Izard

J Med Imaging Radiat Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice.
Jiehua Zhou, Haitang Li, Xin Xia, Alberto Herrera, Nicolette Pollock, David Blakey

Mol Ther· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.
Vikash Reebye, Kai-Wen Huang, Vivian Lin, Sheba Jarvis, Pedro Cutilas, David C Blakey

Oncogene· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer.
Jon Voutila, Vikash Reebye, Thomas C Roberts, Pantelitsa Protopapa, Pinelopi Andrikakou, David C Blakey

Mol Ther· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.
Sarah J Ross, Alexey S Revenko, Lyndsey L Hanson, Rebecca Ellston, Anna Staniszewska, David C Blakey

Sci Transl Med· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.
David Hong, Razelle Kurzrock, Youngsoo Kim, Richard Woessner, Anas Younes, David C Blakey

Sci Transl Med· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling.
Neil R Michaud, Youzhen Wang, Kristen A McEachern, Jerold J Jordan, Anne Marie Mazzola, David C Blakey

Mol Cancer Ther· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.
Naomi Laing, Brenda McDermott, Shenghua Wen, David Yang, Deborah Lawson, David Blakey

Mol Pharmacol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.
Uma Prabhakar, Hiroshi Maeda, Rakesh K Jain, Eva M Sevick-Muraca, William Zamboni, David C Blakey

Cancer Res· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A screening tool to prioritize public health risk associated with accidental or deliberate release of chemicals into the atmosphere.
David H Blakey, Marc Lafontaine, Jocelyn Lavigne, Danny Sokolowski, Jean-Marc Philippe

BMC Public Health· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.
David W Jenkins, Sarah Ross, Margaret Veldman-Jones, Ian N Foltz, Brandon C Clavette, David C Blakey

Mol Cancer Ther· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth.
Simon Tazzyman, Simon T Barry, Susan Ashton, Pauline Wood, David Blakey

Int J Cancer· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding.
Jane Kendrew, Cath Eberlein, Brad Hedberg, Karen McDaid, Neil R Smith, David C Blakey

Mol Cancer Ther· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.
Jin Gao, Jon W Chesebrough, Susan A Cartlidge, Sally-Ann Ricketts, Leonard Incognito, David C Blakey

Cancer Res· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
Gadi Gazit Bornstein, Christophe Quéva, Mohammad Tabrizi, Anne van Abbema, Carlos Chavez, David Blakey

Invest New Drugs· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models.
Jeffrey L Brown, Z Alexander Cao, Maria Pinzon-Ortiz, Jane Kendrew, Corinne Reimer, David C Blakey

Mol Cancer Ther· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International study of factors affecting human chromosome translocations.
Alice J Sigurdson, Mina Ha, Michael Hauptmann, Parveen Bhatti, Radim J Sram, David Blakey

Mutat Res· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo erythrocyte micronucleus assay III. Validation and regulatory acceptance of automated scoring and the use of rat peripheral blood reticulocytes, with discussion of non-hematopoietic target cells and a single dose-level limit test.
Makoto Hayashi, James T MacGregor, David G Gatehouse, David H Blakey, Stephen D Dertinger

Mutat Res· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meeting report: Validation of toxicogenomics-based test systems: ECVAM-ICCVAM/NICEATM considerations for regulatory use.
Raffaella Corvi, Hans-Jürgen Ahr, Silvio Albertini, David H Blakey, Libero Clerici

Environ Health Perspect· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.
Simon P Robinson, Tammy L Kalber, Franklyn A Howe, Dominick J O McIntyre, John R Griffiths, David C Blakey

Neoplasia· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis